Insmed COO Sells $1M in Stock Through Pre-Planned Trading Program

Insider Trading Alert: Roger Adsett, Chief Operating Officer of Insmed, executed significant stock sales on June 16, 2025, through a pre-planned 10b5-1 trading arrangement established on March 4, 2025.

Rhea-AI Filing Summary

Insider Trading Alert: Roger Adsett, Chief Operating Officer of Insmed, executed significant stock sales on June 16, 2025, through a pre-planned 10b5-1 trading arrangement established on March 4, 2025.

Transaction Details:

• First transaction: Sold 6,500 shares at weighted average price of $98.50 (range: $97.93-$98.92)
• Second transaction: Sold 4,186 shares at weighted average price of $99.32 (range: $98.94-$99.83)
• Total shares disposed: 10,686 shares
• Remaining holdings: 130,637 shares held directly

The transactions were executed under a Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by establishing predetermined trading parameters. All shares are held in direct ownership form.

Insider Trade Summary

Net Seller: 10,686 shares

Net Sell 2 txns

Insider Adsett Roger

Role Chief Operating Officer

Sold 10,686 shs ($1.06M)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,500	$98.50	$640K
Sale	Common Stock	4,186	$99.32	$416K

Holdings After Transaction: Common Stock — 130,637 shares (Direct)

Footnotes (3)

1. F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. F2. This is the weighted average sales price representing 6,500 shares sold at prices ranging from $97.93 to $98.92 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
3. F3. This is the weighted average sales price representing 4,186 shares sold at prices ranging from $98.94 to $99.83 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many INSM shares did COO Roger Adsett sell on June 16, 2025?

COO Roger Adsett sold a total of 10,686 shares of INSM common stock on June 16, 2025, consisting of 6,500 shares at an average price of $98.50 and 4,186 shares at an average price of $99.32.

What was the price range for INSM shares sold by Roger Adsett?

The shares were sold in two tranches with different price ranges: The first 6,500 shares were sold at prices ranging from $97.93 to $98.92 per share, and the second tranche of 4,186 shares were sold at prices ranging from $98.94 to $99.83 per share.

How many INSM shares does Roger Adsett own after the June 16, 2025 transactions?

Following the reported transactions, Roger Adsett directly owns 130,637 shares of INSM common stock.

Was the INSM insider sale part of a pre-planned trading arrangement?

Yes, the transactions were executed pursuant to a Rule 10b5-1 trading plan that Roger Adsett adopted on March 4, 2025, in accordance with Securities Exchange Act regulations.

What is Roger Adsett's position at INSM?

Roger Adsett serves as the Chief Operating Officer (COO) of Insmed Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2025 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Adsett Roger

(Last) (First) (Middle)

700 US HIGHWAY 202/206

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		S(1)		6,500	D	$98.5(2)	134,823	D
Common Stock	06/16/2025		S(1)		4,186	D	$99.32(3)	130,637	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

2. This is the weighted average sales price representing 6,500 shares sold at prices ranging from $97.93 to $98.92 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

3. This is the weighted average sales price representing 4,186 shares sold at prices ranging from $98.94 to $99.83 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Remarks:

	/s/ Roger Adsett, by Michael A. Smith as Attorney-in-fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.